Neuroendovascular clinical trials disruptions due to COVID-19. Potential future challenges and opportunities.
aneurysm
standards
stroke
Journal
Journal of neurointerventional surgery
ISSN: 1759-8486
Titre abrégé: J Neurointerv Surg
Pays: England
ID NLM: 101517079
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
11
06
2020
revised:
17
06
2020
accepted:
20
06
2020
pubmed:
2
7
2020
medline:
25
8
2020
entrez:
2
7
2020
Statut:
ppublish
Résumé
To assess the impact of COVID-19 on neurovascular research and deal with the challenges imposed by the pandemic. A survey-based study focused on randomized controlled trials (RCTs) and single-arm studies for acute ischemic stroke and cerebral aneurysms was developed by a group of senior neurointerventionalists and sent to sites identified through the clinical trials website (https://clinicaltrials.gov/), study sponsors, and physician investigators. The survey was sent to 101 institutions, with 65 responding (64%). Stroke RCTs were being conducted at 40 (62%) sites, aneurysm RCTs at 22 (34%) sites, stroke single-arm studies at 37 (57%) sites, and aneurysm single-arm studies at 43 (66%) sites. Following COVID-19, enrollment was suspended at 51 (78%) sites-completely at 21 (32%) and partially at 30 (46%) sites. Missed trial-related clinics and imaging follow-ups and protocol deviations were reported by 27 (42%), 24 (37%), and 27 (42%) sites, respectively. Negative reimbursements were reported at 17 (26%) sites. The majority of sites, 49 (75%), had put new trials on hold. Of the coordinators, 41 (63%) worked from home and 20 (31%) reported a personal financial impact. Remote consent was possible for some studies at 34 (52%) sites and for all studies at 5 (8%) sites. At sites with suspended trials (n=51), endovascular treatment without enrollment occurred at 31 (61%) sites for stroke and 23 (45%) sites for aneurysms. A total of 277 patients with acute ischemic stroke and 184 with cerebral aneurysms were treated without consideration for trial enrollment. Widespread disruption of neuroendovascular trials occurred because of COVID-19. As sites resume clinical research, steps to mitigate similar challenges in the future should be considered.
Identifiants
pubmed: 32606103
pii: neurintsurg-2020-016502
doi: 10.1136/neurintsurg-2020-016502
pmc: PMC7371488
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
831-835Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
J Neurointerv Surg. 2020 Jun;12(6):539-541
pubmed: 32295835
Neurosurgery. 2020 Aug 1;87(2):E203-E206
pubmed: 32358606
Clin Infect Dis. 2020 Nov 19;71(16):2218-2221
pubmed: 32179890
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
Lancet. 2020 Mar 21;395(10228):931-934
pubmed: 32164834
J Neurol Neurosurg Psychiatry. 2020 Aug;91(8):889-891
pubmed: 32354768
Am J Geriatr Psychiatry. 2020 Sep;28(9):913-920
pubmed: 32507686
N Engl J Med. 2020 Apr 30;382(18):1679-1681
pubmed: 32160451
Trials. 2019 May 29;20(1):264
pubmed: 31138317
AJNR Am J Neuroradiol. 2020 Jul;41(7):1136-1141
pubmed: 32439650
N Engl J Med. 2020 May 14;382(20):e60
pubmed: 32343504
J Neurointerv Surg. 2020 Jul;12(7):654-657
pubmed: 32381522
Crit Rev Oncol Hematol. 2020 Jun;150:102972
pubmed: 32344317
Transl Stroke Res. 2020 Jun;11(3):322-325
pubmed: 32378030
Am J Manag Care. 2019 Jan;25(1):40-44
pubmed: 30667610
N Engl J Med. 2018 May 31;378(22):2057-2060
pubmed: 29847763
JAMA Netw Open. 2020 Jun 1;3(6):e2010651
pubmed: 32478845
Head Neck. 2020 Jul;42(7):1516-1518
pubmed: 32348582
NPJ Digit Med. 2020 May 4;3:64
pubmed: 32377575
ESMO Open. 2020 Apr;5(2):
pubmed: 32354722